

**Enterprise Pharmacy and Therapeutics Committee Meeting**  
**Call in number 646-876-9923 Meeting ID 831-139-3271**  
**July 26<sup>th</sup>, 2021**  
**5:00PM-7:00PM CST**

Pre-register at [jplante1@amerihealthcaritasla.com](mailto:jplante1@amerihealthcaritasla.com) prior to the meeting

<u><b>Subject</b></u>	<u><b>Presenter</b></u>
1. Call to Order	B. Himelstein
2. Conflict of Interest Disclosures and Annual Compliance Training	S. Cherian
3. BCC Positive Changes, PA Criteria Updates, DUR Reporting	C. Meny
4. DTM Program Description 2021	C. McMahon
5. Review and approval of May P&T, and June Proxy minutes	S. Cherian
6. Old Business	PerformRx
A. Formulary update .....	p. 150
B. Continuous Glucose Monitors & Insulin Pumps.....	p. 151
7. New Business	PerformRx
A. SGLT-2 and SGLT-2 Combination Products .....	p. 156
B. Allergenic Extracts.....	p. 158
C. Vasodilators for Pulmonary Arterial Hypertension .....	p. 163
D. Calcitonin Gene-Related Peptide (CGRP) Antagonists for Headache Prevention .....	p. 173
E. Acute Migraine Treatments .....	p. 181
F. AHDC – Combination CCB & ACEi/ARB.....	p. 187
G. Medications for Management of Obesity .....	p. 189
H. Promethazine Quantity Limits.....	p. 191
I. Retinoids .....	p. 193
8. Drug Reviews:	PerformRx
A. Therapeutic Class:	
1. Antivirals for Influenza.....	p. 198
2. Artificial Tears .....	p. 203
3. Chelating Agents .....	p. 228
4. IBS-C/IBS-D.....	p. 246
5. Respiratory Aids and Devices.....	p. 262

B. Single Products:	PerformRx
1. Verquvo .....	p. 271
2. Cabenuva .....	p. 278
3. Aduhelm.....	p. 287
4. Empaveli .....	p. 303
5. Myfembree.....	p. 313

9. New Products	PerformRx
-----------------	-----------

10. Prior Authorization Criteria Review:	PerformRx
--	-----------

A. Prior Authorization Criteria Annual Review:	
1. Acthar .....	p. 339
2. Agents for Gender Dysphoria .....	p. 341
3. Anti-FGF23 Monoclonal Antibodies .....	p. 345
4. Antifibrotic Respiratory Tract Agents .....	p. 351
5. Ophthalmic Antihistamines .....	p. 353
6. Oxbryta .....	p. 354
7. Rituximab.....	p. 356
8. Specialty Biological Agents for Ankylosing Spondylitis .....	p. 377
9. Specialty Biological Agents for Crohn's Disease.....	p. 381
10. Specialty Biological Agents for FDA and Non-FDA Approved Medically Accepted Indications.....	p. 385
11. Specialty Biological Agents for Psoriasis .....	p. 390
12. Specialty Biological Agents for Psoriatic Arthritis (PsA).....	p. 395
13. Specialty Biological Agents for Rheumatoid Arthritis .....	p. 400
14. Specialty Biological Agents for Ulcerative Colitis .....	p. 405
15. Spiriva Respimat.....	p. 409
16. Xifaxan.....	p. 411
17. White Blood Cell Stimulators .....	p. 413
18. ACDE – Cinacalcet .....	p. 417
19. BCC – Tysabri .....	p. 419

B. Prior Authorization Criteria Annual Review without Clinical Changes	
1. Adakveo.....	p. 422
2. Adenosine Triphosphate-Citrate Lyase (ACL) inhibitors .....	p. 424
3. Angiotensin II Receptor Blocker and Renin Inhibitor Medications. p.	426
4. Agents for Atopic Dermatitis .....	p. 430
5. Brineura .....	p. 434
6. Budesonide Inhalation Suspension.....	p. 436
7. Crinone (Vaginal Progesterone) .....	p. 438
8. Difucid (Fidaxomicin).....	p. 439
9. Increlex .....	p. 440
10. Mucopolysaccharidosis II (Hunter Syndrome) Agents .....	p. 441
11. Scopalamine Patch.....	p. 442

12. Serostim..... p. 443  
13. Specialty Drugs..... p. 445  
14. Synagis ..... p. 449  
15. Toremifene (Fareston) ..... p. 453  
16. Triamcinolone Intranasal..... p. 454  
17. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors for Huntington's  
Disease..... p. 456  
18. Vimizim ..... p. 460  
19. Voriconazole (Vfend) ..... p. 462  
20. ACDE – Opioid-Containing Products ..... p. 463

11. Recalls

PerformRx

12. Adjourn

B. Himmelstein

**\*\*\*NEXT MEETING: October 25<sup>th</sup>, 2021\*\*\***